RxDoctor Payments Data

Leah Schonfield, DO

Internal Medicine · Dover, NJNPI 1265530208

Payments from drug & device makers

$1,597in general payments, 2019–2025

Across 82 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$439
  • Exact Sciences$254
  • Novo Nordisk$157
  • Merck$148
  • AstraZeneca$138
  • GSK$134
  • plus $327 from 10 others

What the payments were for

  • Food & beverage$1,597100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,597 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$122,721
Medicare patients
195
Services billed
1,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin22$37,007
JanuviaSitagliptin Phosphate21$27,674
AbrysvoRsv Vacc, Pref A And Pref B/Pf55$17,314
RybelsusSemaglutide11$14,748
OzempicSemaglutide13$13,644
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,338
Valsartan82$2,344
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,230
Atorvastatin Calcium258$2,181
SynthroidLevothyroxine Sodium23$1,824
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf22$1,499
Metoprolol Succinate80$1,306
Simvastatin125$1,271
Rosuvastatin Calcium113$1,102
Levothyroxine Sodium135$1,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$37,00722 claims
Novo NordiskRybelsus, Ozempic$157$28,39224 claims
MerckJanuvia$148$27,67421 claims
PfizerAbrysvo$439$17,31455 claims
GSKShingrix$134$3,33815 claims
AbbVieSynthroid$44$1,82423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Dover

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →